Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Namrata S. Patil(Gene Therapy Laboratory), David S. Shames(The University of Texas Southwestern Medical Center), Allison W. Hsia, Shyam Srivats, Sören Müller(University of California, San Francisco), Chikara Takahashi, Sangeeta Jayakar, Maureen Peterson, Hartmut Koeppen, Romain Banchereau, Jennifer M. Giltnane, Avantika S. Chitre, Amelia Au‐Yeung, William O’Gorman, Jason Cheng, Wei Zou, Linda Rangell, Jane L. Grogan, Patrícia E. de Almeida, Marcus Ballinger, Barzin Y. Nabet(Gene Therapy Laboratory)

Cancer Cell

February 24, 2022

10.1016/j.ccell.2022.02.002

Cited by 403

Related Papers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

|The Lancet|2016|4.8k

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

|New England Journal of Medicine|2018|3.5k

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

|Nature Immunology|2008|1.5k

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

|Nature Medicine|2018|1.2k